---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-073593"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2026-06-12T21:25:19+00:00"
generated_at: "2026-06-12T21:26:37.920367+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Traws Pharma defers Phase 2a test of tivoxavir marboxil after UK MHRA review

## Summary
- Phase 2a human influenza challenge study for TXM deferred due to negative UK MHRA review.
- Tivoxavir marboxil retains potential for emergency bird flu use per CSO Pauza.
- Company advancing backup influenza candidates with TXM's PK profile and no mutagenic potential.
- Cash runway extends to Q1 2027; CEO confirms commitment to long-acting influenza antivirals.

## SEC filing metadata
- accession: 0001104659-26-073593
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2026-06-12T21:25:19+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465926073593/0001104659-26-073593-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465926073593/tm2617872d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-073593
- JSON: https://secwatch.observer/filing/0001104659-26-073593.json
- Plain text: https://secwatch.observer/filing/0001104659-26-073593.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.